Drug intelligence / Profile preview

autologous bone marrow-derived CD133+ cells

Development stage: Unknown
Lead developer: Royan Institute
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

Autologous bone marrow-derived CD133+ cells is an investigational cell therapy developed by the Royan Institute for the treatment of osteonecrosis of the femoral head (ONFH). The therapy utilizes CD133+ hematopoietic stem and progenitor cells isolated from the patient's own bone marrow. These cells are delivered via injection into the necrotic site of the femoral head, typically in conjunction with core decompression surgery. The therapeutic rationale is that these cells promote angiogenesis and osteogenesis, facilitating the restoration of blood supply and bone regeneration in the ischemic tissue.

Other names: CD133+ cellsCD133+ stem cellsautologous CD133+ cells

Beyond the preview

Go deeper on autologous bone marrow-derived CD133+ cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bone marrow-derived CD133+ cells.

Explore the full profile